Ads
related to: fda approves new prostate cancer treatment- nmCRPC Treatment Option
31% Risk of Death Decrease
Visit The Patient Site.
- Dosing & Administration
View Recommended Dosage & Learn
About Drug Interactions Here.
- mHSPC Treatment Option
32% Risk of Death Decrease
Visit The Patient Site.
- Clinical Information
Read About A Double-Blind, Placebo-
Controlled, Randomized Study.
- Downloadable Resources
Resources For Physicians & Patients
Available On The Site To Download.
- Patient Profiles
Explore Patient Profiles To Assess
A Treatment Option.
- nmCRPC Treatment Option
Search results
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional...
Morningstar· 5 days agoXTANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurrent non-metastatic hormone-sensitive prostate< ...
Is the FDA Pausing More Cancer Trials? It's Hard to Tell
Medscape· 4 days agoIs the FDA Pressing Pause on More Cancer Trials? In October, the US Food and Drug Administration (...
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric...
WTVO - WQRF Rockford· 5 days agoNovartis today announced that the U.S. Food and Drug Administration (FDA) approved Lutathera® (lutetium Lu 177 dotatate) for the treatment</ ...
20 Counties with the Highest Cancer Rates in the US
Insider Monkey via Yahoo Finance· 3 days agoIn this article, we will be taking a look at the 20 counties with the highest cancer rates in the US. If you do not want to learn about the global impact...
Vitamin D may improve gut health, aid cancer immunotherapy treatments
Medical News Today· 3 days agoPrevious research has looked at using vitamin D in conjunction with cancer immunotherapy....
PSA Detectable After Radical Prostatectomy
Medscape· 5 days agoFollowing radical prostatectomy, however, approximately 20%-40% of patients with localized disease will experience biochemical recurrence.
MD Anderson Research Highlights for April 24, 2024
Newswise· 4 days agoThe University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These adva
AstraZeneca’s Lynparza to remain dominant in PARP inhibitors market with $4 billion in sales by 2027
BioPharma-Reporter· 3 days agoWhile the PARP inhibitors market has seen increasing competition over the years, Lynparza is set to...
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
Zacks via Yahoo Finance· 5 days agoARV-766 is Arvinas’ second-generation PROTAC androgen receptor (AR) degrader. The candidate is...
Ads
related to: fda approves new prostate cancer treatment
